A phase I trial (NCT01974661) confirmed the safety of intra-tumoral injection of ilixadencel (pro-inflammatory allogeneic DCs stimulated by GM-CSF and IL-4), either as monotherapy or in combination with sorafenib, and was associated with increased tumor-specific CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.